Equities

Zhejiang Ausun Pharmaceutical Co Ltd

603229:SHH

Zhejiang Ausun Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)8.28
  • Today's Change-0.540 / -6.12%
  • Shares traded13.28m
  • 1 Year change-22.51%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zhejiang Ausun Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of specialty bulk pharmaceutical chemicals (BPCs) and pharmaceutical intermediates. The Company's main products include bimatoprost, latanoprost, latanoprostene bunod, entecavir, selectfluor and other intermediates. The Company is also involved in the provision of customized production, as well as research and development services to customers through its subsidiaries.

  • Revenue in CNY (TTM)835.23m
  • Net income in CNY257.55m
  • Incorporated2010
  • Employees1.17k
  • Location
    Zhejiang Ausun Pharmaceutical Co LtdNo. 5, Donghai 4th Avenue, Linhai ParkChemcial Raw Materials Pharmaceutical BaTAIZHOU 317016ChinaCHN
  • Phone+86 57 685589367
  • Fax+86 57 685589367
  • Websitehttps://www.ausunpharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sichuan Huiyu Pharmaceutical Co Ltd1.12bn278.20m6.85bn1.36k24.641.77--6.120.65670.65672.649.160.23351.1821.25820,954.905.6610.417.0812.7683.4089.8924.2321.422.57--0.148820.54-37.9276.37-43.86--66.72--
Shanghai Fudan-Zhangjiang Bio-Pharm. Co691.62m105.20m6.90bn948.0085.943.78--9.970.09980.09980.65092.270.24821.531.50729,558.103.767.034.439.0590.2492.1715.1517.266.06--0.004826.31-17.502.78-21.28-0.632620.49--
JiangSu WuZhong Pharmactcl Devlpm Co Ltd2.38bn-37.82m7.14bn1.05k--3.97--2.99-0.055-0.0553.342.520.568417.732.042,270,402.00-0.8772-2.92-1.79-5.3028.0728.14-1.54-5.771.460.51270.4841--10.555.655.58---19.08--
Lushang Freda Pharmaceutical Co Ltd3.99bn236.52m7.20bn3.65k30.431.76--1.810.23270.23273.924.020.46940.79417.741,091,879.003.230.69925.935.1248.7320.236.873.452.96--0.089640.33-64.65-12.29567.4413.3644.4014.87
China Animal Husbandry Industry Co., Ltd5.43bn87.90m7.30bn4.33k83.071.33--1.350.08610.08615.315.370.61274.563.761,254,216.000.70856.231.009.0116.4224.291.168.691.54--0.190931.20-8.244.04-26.73-0.612724.20-3.77
Zhejiang Ausun Pharmaceutical Co Ltd835.23m257.55m7.32bn1.17k28.353.19--8.770.31110.31111.012.760.27881.092.84711,439.108.609.3811.3512.8454.3453.0930.8427.142.00--0.15623.536.8327.357.8742.0724.3250.48
Jinyu Bio-Technology Co Ltd1.35bn164.86m7.73bn1.65k46.511.42--5.730.14840.14841.214.840.1972.101.62816,227.802.364.822.745.6854.6058.7811.9719.913.12--0.007936.414.55-3.3734.63-17.77-12.92-25.56
Beijing Foyou Pharma Co Ltd3.42bn510.00m7.81bn3.44k15.322.20--2.281.061.067.137.390.76223.649.70996,443.0011.43--14.76--65.53--14.99--2.73--0.0245--3.07--11.36------
Data as of Nov 22 2024. Currency figures normalised to Zhejiang Ausun Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

1.79%Per cent of shares held by top holders
HolderShares% Held
Guotai Asset Management Co., Ltd.as of 30 Jun 20243.40m0.41%
The Vanguard Group, Inc.as of 06 Nov 20242.16m0.26%
China Southern Asset Management Co., Ltd.as of 30 Jun 20241.94m0.23%
CCB Principal Asset Management Co., Ltd.as of 30 Jun 20241.88m0.23%
China Asset Management Co., Ltd.as of 30 Jun 20241.42m0.17%
GF Fund Management Co., Ltd.as of 30 Jun 20241.01m0.12%
Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2024920.63k0.11%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024842.52k0.10%
Essence Fund Co., Ltd.as of 30 Jun 2024664.16k0.08%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024632.94k0.08%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.